Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024

Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.

Essity Aktiebolag (publ): 1 director

A director at Essity Aktiebolag (publ) bought 12,008 shares at 273.140SEK and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Modern Times Group AB: 3 directors

Three Directors at Modern Times Group AB bought/maiden bought 3,152 shares at 6.574SEK. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...

Striving to improve margins - up to BUY

Weather weight as expected, but a more bullish margin story evolving. We increase our estimates by 5-10% from improved UW. Up to BUY (Hold) with TP NOK 195 (171); 10% upside.

Essity (Buy, TP: SEK330.00) - Financial targets up next

The solid Q1 results were aided by the ongoing gross margin recovery, YOY and QOQ. We expect investor focus from here to be on whether Essity can offset rising raw material costs through agility and pricing power. We see new financial targets and capital allocations as the next potential share-price catalysts; we reiterate our BUY and have edged up our target price to SEK330 (325).

Pulp fiction in Q1, reality for Q2

Gjensidige Forsikring (Buy, TP: NOK197.00) - Turning point in sight

Harsh weather during Q1 led to elevated claims and a combined ratio deterioration of 5.7%-points YOY despite insurance revenues growing 11% YOY. Adjusting for weather and other items, the claims ratio improved 0.2%-points YOY, a sign that the sharp repricing efforts during 2023 are starting to take effect. Combined with signs of abating claims frequencies and further repricing, we expect continued underwriting improvements. We reiterate our BUY, having raised our 2025–2026e EPS by 3% and our tar...

MTG (Buy, TP: SEK120.00) - Profitable growth and buybacks

We reiterate our BUY and have raised our target price to SEK120, following a >10% earnings beat in Q1. MTG gave a cautious revenue growth outlook for 2024 (+1-5% YOY) but with positive adj. EBITDA margin guidance (26–29%). It announced SEK100m of buybacks, with more likely to come following the AGM on 16 May. We have raised our 2024–2025e EBITDA by c3% and continue to like the MTG story, with market growth, good cost control and the ~SEK3bn net cash position.

Essity (Buy, TP: SEK325.00) - Good Q2, but no buybacks

We consider this a positive report for Essity, with Q1 adj. EBITA 10% above consensus, mainly driven by a strong gross margin. That said, no financial targets or buybacks following the Vinda transaction were announced, and we expect any conference call comments to be in focus. We expect consensus 2024e adj. EBITA to come up c2% on the results and expect a positive share price reaction.

Weather weighs on underwriting; life beat (corrected)

Adj. PTP -7% vs IR cons, -3% vs ABGSCe, as reported CR 92.6%. High premium growth of 11%, in line with us and cons. Cons. est. -1% to -3% amid UW, life mute; stock -1% to -4%

Tryg (Buy, TP: DKK185.00) - Continued underlying improvement

Q1 PTP was down 15% YOY to DKK1,007m (as we and consensus expected), reflecting the harsh winter weather and a high-profile claim in Sweden. However, the underlying claims ratio extended its long run of improvements, ending 0.5%-points stronger YOY. Given the ongoing premium repricing and CMD in December, we expect focus to remain on maintaining underwriting discipline, supporting continued improvements. We have made limited changes to our 2025–2026e net profit, and reiterate our BUY and DKK185 ...